GLP-1 drugs don’t have a long interaction list in the traditional enzyme-inhibition sense — they have one big mechanism that touches everything you swallow, plus a handful of specific label warnings that deserve to be famous. This file covers all of it: what the labels actually say, what to monitor, and what to bring up with your prescriber and pharmacist.
The master mechanism: your stomach slows down
Every clinically interesting GLP-1 interaction starts from the same fact: these drugs delay gastric emptying, most strongly in the first weeks after starting and after each dose increase. A pill sitting longer in the stomach can be absorbed later, more slowly, or — for a few drug categories — differently enough to matter. For most medications, studies show the effect is modest and clinically insignificant. The exceptions are drugs where timing and blood levels are unforgiving: narrow-therapeutic-index medications, where small changes have real consequences.
Levothyroxine: the interaction hiding in plain sight
Thyroid hormone replacement is fussy about absorption in the best of times — empty stomach, consistent timing, spaced away from coffee and calcium. Add a drug that reshapes stomach emptying and the potential for drift is obvious; studies with oral semaglutide observed meaningfully increased levothyroxine exposure, and clinical guidance converges on one answer: keep your levothyroxine routine rigidly consistent, and check TSH about 6–8 weeks after starting a GLP-1 or changing its dose. Symptoms of thyroid drift — fatigue, palpitations, temperature intolerance — warrant an earlier check. If you take Rybelsus, the choreography question (which empty-stomach drug goes first?) is a pharmacist conversation, not a guess; the standard approach separates them and monitors.
Warfarin and other fussy old drugs
Warfarin’s INR responds to almost anything — diet shifts, appetite changes, and altered absorption all move it, and a GLP-1 introduces all three at once. The labels advise monitoring; practically, that means an INR check within a week or two of starting or escalating, then per your clinic’s judgment. The same heightened-attention logic applies to other narrow-window drugs: certain seizure medications, transplant immunosuppressants like tacrolimus, lithium, and digoxin. None are forbidden; all deserve a level check after GLP-1 initiation and a pharmacist review of timing.
Insulin and sulfonylureas: the hypoglycemia stack
This is the interaction with teeth. GLP-1s lower glucose in a glucose-dependent way — alone, they rarely cause serious lows. Stacked on insulin or a sulfonylurea (glipizide, glyburide, glimepiride), they can, and the labels say so directly: dose reductions of the older agents are commonly needed when a GLP-1 starts. If you have diabetes and your prescriber adds a GLP-1 without discussing your insulin or sulfonylurea dose, ask the question yourself. Know the hypoglycemia symptoms — shakiness, sweating, confusion, racing heart — and keep fast sugar at hand during the transition weeks.
Tirzepatide and birth control: the rule that surprises everyone
Unique to tirzepatide among approved agents: the label states oral hormonal contraceptives may be less effective around initiation and dose escalation, and instructs adding a barrier method or switching to a non-oral contraceptive for four weeks after starting and after each dose increase. Semaglutide’s dedicated studies found no meaningful contraceptive-exposure change, so the rule does not extend to it. Given how often tirzepatide doses step up in the first year, this is effectively a recurring rule, not a one-time one — the full reproductive-health picture is in the pregnancy and fertility file.
Other diabetes and weight medications
Metformin pairs routinely with GLP-1s — no dose interaction, though their GI side effects can add up during titration. SGLT2 inhibitors, statins, and blood-pressure medications have no notable interaction, with one nuance: as weight falls, blood pressure often falls with it, and antihypertensive regimens sometimes need trimming — a monitoring point, not a danger. Combining a GLP-1 with another GLP-1 or with older weight drugs is unstudied territory the labels warn against duplicating; that includes stacking a prescription with gray-market peptides, covered in the warning file.
Alcohol
Not a label interaction, but a real-world one: reduced desire and slower gastric handling change how drinking feels, and alcohol plus insulin or sulfonylureas raises hypoglycemia risk further. The emerging craving science and practical guidance live in the alcohol file.
Supplements and “natural Ozempic” claims
Berberine and similar supplements marketed as GLP-1 alternatives have modest, inconsistent evidence and their own interaction profiles (berberine notably affects drug-metabolizing enzymes). Taking them alongside a real GLP-1 adds unpredictability without documented benefit. Tell your prescriber everything you take — the interaction review only works on a complete list.
Anesthesia and procedures
The delayed-emptying mechanism is also why every surgical, endoscopy, and anesthesia team needs to know you’re on these drugs — aspiration risk planning and hold-the-dose guidance have their own evolving standards, covered fully in the surgery guide.
The checklist
Before starting: give prescriber and pharmacist your complete medication and supplement list; ask specifically about insulin/sulfonylurea reductions if applicable; plan contraception per the tirzepatide rule; schedule TSH or INR checks if you take levothyroxine or warfarin. After each dose increase: repeat the contraception window if on tirzepatide; watch narrow-window drug symptoms; recheck labs your clinician flagged. Ongoing: one pharmacy or one complete med list, so somebody sees the whole board.
The bottom line
One mechanism explains most of it: a slower stomach makes swallowed drugs less predictable, which matters only for the unforgiving ones. The specific rules worth memorizing are three — tirzepatide’s four-week contraception window, the insulin/sulfonylurea reduction conversation, and lab checks for levothyroxine and warfarin. Everything else is disclosure and monitoring, which cost nothing and catch what matters.
Timing strategies that actually help
Injection timing is flexible — the labels allow any time of day — so use that freedom deliberately. Many people inject in the evening so peak early side effects overlap sleep; people juggling fussy morning medications (levothyroxine especially) often prefer that arrangement since the injection then never competes with the morning routine at all. For oral medications generally, consistency beats optimization: same times, same food context, every day, so that whatever absorption shift the GLP-1 causes is at least a stable one your labs can capture. And route around the stomach where routes exist — the tirzepatide contraception rule is easiest to satisfy with a non-oral method precisely because it takes gastric emptying out of the equation entirely.
Three worked scenarios
The levothyroxine patient starting tirzepatide. She keeps her 6 a.m. empty-stomach levothyroxine ritual untouched, moves her weekly injection to Sunday evenings, switches from the pill to an IUD after the contraception conversation (solving the four-week rule permanently), and books a TSH draw for week seven. Nothing dramatic — which is the point.
The type 2 diabetes patient on insulin glargine and glipizide adding semaglutide. His prescriber cuts the glipizide in half on day one and arms him with a glucose meter schedule and low-sugar protocol; two mild morning lows in week three prompt stopping the sulfonylurea entirely. This is the interaction file’s highest-stakes lane, and it went well because the dose-reduction conversation happened before the first injection, not after the first low.
The transplant recipient on tacrolimus. Her transplant team — looped in before starting, not after — orders trough levels at two and six weeks post-initiation and after each dose escalation. Levels drift modestly; the team adjusts; nothing is left to chance, because with a transplanted organ nothing should be.
Questions worth asking your pharmacist
Five that cover most of the board: Which of my current medications are narrow-therapeutic-index? Should any doses change when I start this? Which of my labs should be rechecked, and when? Does my injection timing interact with anything I take by mouth? And — the catch-all — is there anything on my profile you’d watch? Pharmacists run interaction software all day; a sixty-second consult at pickup is the cheapest safety check in medicine.
Mini-FAQ
Can I take ibuprofen or acetaminophen? No direct interaction with either; standard NSAID cautions (stomach irritation, kidney stress if dehydrated) apply and matter slightly more during heavy-nausea weeks — hydrate. Antidepressants? No label interaction with SSRIs/SNRIs; appetite and weight effects can compound in either direction, worth mentioning to whoever manages your mental-health care. Proton-pump inhibitors? Compatible; no adjustment needed. Vitamins and supplements? Fine, but disclose everything — “natural” products (berberine again) are drugs the interaction software can’t see unless you name them. Does the interaction risk fade over time? The gastric-emptying effect attenuates somewhat with continued use, but every dose escalation refreshes it — which is why the tirzepatide contraception window and the recheck-your-labs advice both key off dose changes, not just initiation.
When to call: immediately versus routinely
Immediately: hypoglycemia symptoms while on insulin or a sulfonylurea (treat first with fast sugar, then call); signs of thyroid drift on levothyroxine — racing heart, unusual fatigue, heat or cold intolerance; any bleeding or bruising change on warfarin; and for transplant patients, anything your team told you always warrants a call, because with them it always does. Routinely, at the next appointment: questions about spacing oral medications, whether an antihypertensive should shrink as weight falls, supplement additions, and every planned dose escalation — which, on tirzepatide, also resets the contraception clock. The dividing principle is simple: symptoms in a narrow-window drug’s territory jump the queue; logistics wait their turn. And when in doubt about which side of that line you’re on, the pharmacy phone line exists precisely for the doubt.
Sources
Zepbound/Mounjaro and Wegovy/Ozempic/Rybelsus prescribing information (drug-interaction sections); levothyroxine exposure data from oral semaglutide clinical pharmacology; class labeling on concomitant insulin secretagogues. Full trial citations live in the linked files.